Roger McIntyre, MD, FRCPC, will share data on the safety and efficacy of an FDA-approved atypical antipsychotic with a new indication as an adjunctive therapy to antidepressants for the management of MDD in adults with partial response to...
Roger McIntyre, MD, FRCPC, will share data on the safety and efficacy of an FDA-approved atypical antipsychotic with a new indication as an adjunctive therapy to antidepressants for the management of MDD in adults with partial response to...
Vlad Maletic, MD, and Craig Chepke, MD, will go head-to-head in a 1-hour debate to discuss neurotransmitter modulation vs neural network modulation in MDD. Join us on 3/22 at 1pm ET & 3/28 at 3pm ET. Register today!
Vlad Maletic, MD, and Craig Chepke, MD, will go head-to-head in a 1-hour debate to discuss neurotransmitter modulation vs neural network modulation in MDD. Join us on 3/22 at 1pm ET & 3/28 at 3pm ET. Register today!
Jeremy Schreiber, MSN, PMHNP-BC, teaches effective communication skills and strategies for mental health screening, diagnosis, treatment, monitoring, and remote care. Sign up today!
Jeremy Schreiber, MSN, PMHNP-BC, teaches effective communication skills and strategies for mental health screening, diagnosis, treatment, monitoring, and remote care. Sign up today!
Kali Cyrus, MD, MPH, assistant professor of psychiatry at Johns Hopkins School of Medicine (Washington, DC), considers the heterogeneity of stigma around major depression and how this impacts efforts to reduce it.
Kali Cyrus, MD, MPH, assistant professor of psychiatry at Johns Hopkins School of Medicine (Washington, DC), considers the heterogeneity of stigma around major depression and how this impacts efforts to reduce it.
Kali Cyrus, MD, MPH, assistant professor of psychiatry at Johns Hopkins School of Medicine (Washington, DC), discusses the roles of education and community outreach in addressing the stigma around major depressive disorder (MDD).
Kali Cyrus, MD, MPH, assistant professor of psychiatry at Johns Hopkins School of Medicine (Washington, DC), discusses the roles of education and community outreach in addressing the stigma around major depressive disorder (MDD).
Jeremy Schreiber, MSN, PMHNP-BC, teaches effective communication skills and strategies for mental health screening, diagnosis, treatment, monitoring, and remote care. Sign up today!
Jeremy Schreiber, MSN, PMHNP-BC, teaches effective communication skills and strategies for mental health screening, diagnosis, treatment, monitoring, and remote care. Sign up today!
Qelbree® (viloxazine extended-release capsules) is an FDA-approved medication indicated to treat Attention-deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.
Qelbree® (viloxazine extended-release capsules) is an FDA-approved medication indicated to treat Attention-deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.